Now Available - The Next-Generation Percepta Genomic Sequencing Classifier (GSC)


Improving Confidence in
Lung Disease Diagnosis

Veracyte designs actionable genomic tests that help resolve diagnostic uncertainty in lung cancer and interstitial lung disease.

Select a product below to learn more

What Do You Do With Inconclusive
Diagnostic Bronchoscopies?

Percepta GSC classifies the risk of primary lung cancer to guide patient management when bronchoscopy is inconclusive.

The Percepta GSC measures gene expression alterations in bronchial epithelial cells collected from two brushings of the main stem airway of current or former smokers.

Be one of the first to offer the next-generation Percepta classifier to your patients.

Sign Up for Percepta GSC

Want to Learn More About Percepta GSC?

Veracyte's Medical Director, Dr. Sangeeta Bhorade, discusses the features, performance and development of Percepta GSC in a recorded clinical webinar. Select from any available event and register to watch.

View Webinar

Include Percepta GSC in Your Practice

Fast and simple to collect and order—
Percepta integrates seamlessly into your practice.

How confident are you in
your ILD/IPF diagnosis?

Envisia genomic classifier enables more confident IPF diagnosis by detecting a genomic pattern of UIP through transbronchial biopsy.

Up to 60% of patient cases with histopathologic UIP findings are missed by High Resolution CT (HRCT) alone.2,3 Envisia classifier is designed as a complement to HRCT and clinical factors for a more confident IPF diagnosis.

Be one of the first to offer this test.

sign up for the early access program

Newly published data in Lancet Respiratory Medicine demonstrated the Envisia classifier results informed ILD clinical diagnoses by identifying UIP with 88% specificity and 70% sensitivity.2

Read the Validation Study

CALL US at 1-877-822-4013

Want to learn more? Fill out this form and we’ll follow up with you.

*For intermediate pre-test risk patients.
**Compared to Patients with a Positive Result.